

Lupus Immune Monitoring Solutions With Epiontis ID

The unpredictable relapsing-remitting course and the clinical heterogeneity of systemic lupus erythematosus (SLE) pose a challenge for effective clinical trial design. Many promising, novel approaches to lupus therapy have missed their primary endpoints in recent years.

Frequent immune monitoring of lupus patients may provide crucial information that can support successful clinical trials. Epiontis ID provides a wide portfolio of assays that monitor cell types relevant in lupus.

Key Cell Types Rapidly Quantified via Prevalidated Epiontis ID Panels

Treg & Th17 Cell Balance:

- Abnormal levels may correlate with disease severity in lupus patients
- Simple to measure via Epiontis ID; can be challenging via other methods

Neutrophils, T Cells, B Cells, NK Cells:

- Neutrophil to lymphocyte ratio (NLR) increase is common in lupus patients
- Rare cell type in blood; more easily measured via Epiontis ID

B Cells, Memory B Cells, Tfh Cells:




- B-cell hyperactivity and breach of tolerance constitute hallmarks of lupus
- Epiontis ID offers reliable monitoring, both in blood or tissue

Plasmacytoid Dendritic Cells (pDC):

- Source of uncontrolled type 1 IFN production in SLE
- Rare cell type in blood; more easily measured via Epiontis ID

Next Generation Immune Monitoring With Epiontis ID

Epiontis ID is an immune monitoring service supporting the development of today's most innovative therapeutics, allowing researchers to profile and uncover specific changes to the immune system by measuring cell type-specific epigenetic markers in DNA.

 <p>Precise and Reproducible Results</p> <p>Operator-independent technology for consistent results within and across studies</p>	 <p>Increased Study Flexibility</p> <p>Analyze fresh or frozen whole blood, dried blood spots, and even tissue</p>	 <p>Simplified Logistics</p> <p>No need for complex sample preparation or rushed shipments</p>	 <p>Rapid Data Delivery</p> <p>With over 30 prevalidated cell type assays, data can be delivered within days of project initiation</p>	 <p>Proven Clinical Utility</p> <p>Over 68,000 samples analyzed across more than 100 clinical trials; dozens of study sponsor posters and publications</p>
--	--	--	--	--

Over 30 prevalidated cell types available including:

- Overall CD3 T cells
- 8 additional T cell subtypes including Treg, Tfh, Th17
- B cells, naive/memory B cells
- All granulocyte subtypes
- Monocytes, myeloid MDSC
- Plasmacytoid dendritic cells
- Exhaustion markers: PD1+ and LAG3+ cells
- Activation markers: CXCR3+, CCR6+, CCR7+, GNLy+
- Migration markers: ITGA4+, S1PR1+, S1PR5+, CRTH2+
- Other cell types, including fibrocytes

An Ideal Tool for Autoimmune Clinical Studies

Epiontis ID has been used in numerous phase 1 to phase 4 clinical studies, and is an ideal tool to support autoimmune therapeutic development, as demonstrated by the use of Epiontis ID in specific autoimmune indications.

Autoimmune Indication	No. of Studies	Study Phase	Sample Types
Asthma	2	Phase 2b	Blood
Atopic dermatitis	5	Research, phase 1b, 2a, 2b	Blood, tissue
Behcet's syndrome	1	Phase 4	Blood
Celiac disease	1	Preclinical	Blood
Chronic rhinosinusitis	1	Phase 2a	Blood
Chronic spontaneous urticaria	1	Research	Blood, tissue
Crohn's disease	4	Phase 3	Blood
Crohn's, MS, ulcerative colitis	2	Phase 1	Blood
Diabetes	2	Research, phase 2	Blood, cells
GvHD	5	Phase 3	Blood, tissue, PBMC, cells
IBD	1	Preclinical	Tissue
Lupus	3	Phase 1, 2	Blood
Multiple sclerosis	2	Phase 1, 2	Blood
Myasthenia gravis	1	Phase 2	DNA
Peanut allergy	1	Preclinical	Blood
Psoriasis	7	Phase 1, 1b, 2, 4	Blood, tissue
Rheumatoid arthritis	4	Research, phase 1b, 2, 2b	Blood
Sjogren's syndrome	5	Phase 1, 2a	Blood, DNA, PBMC
Ulcerative colitis	2	Phase 2	Blood, tissue

For more information about Epiontis ID, please visit Epiontis.com.